Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combination tested against standard chemo for recurrent ovarian cancer

NCT ID NCT07821606

Disease control Sponsor: Hansoh BioMedical R&D Company Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 16, 2026 · Last updated Sep 17, 2026 · Updated 1 time

Summary

This phase III trial compares an experimental drug, HS-20089, given with bevacizumab against standard platinum-based chemotherapy plus bevacizumab in women with platinum-sensitive recurrent ovarian cancer. About 460 participants will be randomly assigned to one of the two treatment groups. The main goal is to see which approach keeps the cancer from growing for longer, measured by progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
HS-20089, an experimental drug, given with bevacizumab
What this could lead to
If it works, HS-20089 plus bevacizumab could offer a new treatment option for women whose ovarian cancer has come back after platinum chemotherapy.
What could go wrong
HS-20089 is still experimental, and combining it with bevacizumab may not control the cancer better than standard chemotherapy. The trial could also show more side effects than the standard regimen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 460 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Nov 2026

An estimate. Start dates often move.

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- The main criteria are as follows: 1. Female, aged 18 years or older (≥18 years) 2. Willing to voluntarily participate in this clinical trial, understand the study procedures, and able to provide written informed consent 3. Platinum-sensitive recurrence 4. ECOG PS: 0-1 5. Expected survival of more than 12 weeks. 6. Women of childbearing potential must be willing to use appropriate contraceptive measures from the time of signing informed consent until 6 months after the last dose administration and should not be breastfeeding. 7. Must be able to provide sufficient fresh or archived tumor tissue specimens that meet the requirements. Exclusion Criteria: * 1\. Prior treatment with topoisomerase I inhibitors; cytotoxic chemotherapy agents; small molecule inhibitors; antibody-drug conjugates (ADCs). 2\. Prior major surgery within 4 weeks prior to radonmization. 3. Residual toxicity from previous treatments graded ≥ Grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 6.0. 4\. History of a second primary malignancy. 5. Pleural effusion/ascites requiring clinical intervention); presence of pericardial effusion. 6\. Imaging evidence of bowel obstruction or symptoms/signs suggestive of bowel obstruction. 7 History of gastrointestinal perforation or fistula, or any grade of intra-abdominal abcess within 3 months prior to randonmization. 8 Participants known to have central nervous system (CNS) metastases and/or carcinomatous meningitis, either previously diagnosed or identified during screening. 9 Severe or poorly controlled hypertension. 10 Clinically significant bleeding symptoms 11 History of severe arterial/venous thromboembolic events 12. Clinically significant active viral, bacterial, or fungal infections requiring intravenous or oral pharmacological treatment 13. Known presence of an active infectious disease 14. History of interstitial lung disease of any grade

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Platinum-sensitive recurrent ovarian cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Platinum-sensitive recurrent ovarian cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    39 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Anhui Provincial Hospital

    Hefei, Anhui, 230001, China

  • Anyang Cancer Hospital

    Anyang, Henan, 455000, China

  • Chongqing University Cancer Hospital

    Chongqing, Chongqing Municipality, 400030, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, 200032, China

  • Guangxi Medical University Cancer Hospital

    Nanning, Guangxi, 530021, China

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, 150081, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, 430079, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410013, China

  • Jiangsu Cancer Hospital

    Nanjing, Jiangsu, 210009, China

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210029, China

  • Jiangxi Cancer Hospital

    Nanchang, Jiangxi, 330029, China

  • Jiangxi Maternal and Child Health Hospital

    Nanchang, Jiangxi, 330006, China

  • Liaoning Cancer Hospital

    Shenyang, Liaoning, 110042, China

  • Linyi People's Hospital

    Linyi, Shandong, 276000, China

  • National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 1000021, China

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, 100730, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, 100142, China

  • Qilu Hospital of Shandong University

    Jinan, Shandong, 250012, China

  • Shandong Cancer Hospital

    Jinan, Shandong, 030013, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, 03001, China

  • Shengjing Hospital of China Medical University

    Shenyang, Liaoning, 110004, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, 510060, China

  • The Affiliated Hospital of Southwest Medical University

    Luzhou, Sichuan, 646000, China

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, 325015, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi’an, Shanxi, 710061, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, 361003, China

  • The First Hospital of Jilin University

    Changchun, Jilin, 130021, China

  • The Second Affiliated Hospital of Zhejiang University

    Hangzhou, Zhejiang, 310009, China

  • The Second Hospital of Jilin University

    Changchun, Jilin, 130041, China

  • Tianjin Cancer Hospital

    Tianjin, Tianjin Municipality, 300060, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430030, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, 430022, China

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan, 610041, China

  • Xuzhou Central Hospital

    Xuzhou, Jiangsu, 221009, China

  • Yuebei People's Hospital

    Shaoguan, Guangdong, 512026, China

  • Yunnan Cancer Hospital

    Kunming, Yunnan, 650118, China

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, 310022, China

  • Zhejiang People's Hospital

    Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.